Explore the vast range of titles available.

This book provides a comprehensive history of the COVID-19 pandemic. At first glance, the pandemic struck as a natural disaster, with the sudden emergence of a virus as a major threat from outside. However, the pandemic has a history. SARS-COV-2 arrived in a world that was already very much focused on viruses, health, and longevity, and in which the fear of epidemics had already led to the mobilization of knowledge, technology, and a wide range of institutions to prepare us. The book develops the argument that these pre-existing structures and sensitivities have to a large extent determined the political and other reactions to the SARS-COV-2 virus and how the debates on the measures to halt its circulation have unfolded.

Covid-19 has created trauma, death and destruction as well as challenged us for transformation of our existing society, economy and polity. The book engages with the challenges of transformations as a consequence of this. It brings reflections from several disciplines and thought practitioners from around the world. It explores challenges of transformations in economics, politics, self, science and society for living meaningfully in a post-pandemic world. It also explores pathways of creative planetary futures that we need to cultivate with and beyond Covid-19.

Non-Essential Humans, is both a critical documentation and commentary on the world that Covid-19 created.It focuses on the diametric, but supposedly harmonious ways in which the state on the one hand, and the governed on the other, responded to their progressively altering and scary worlds.

This book details all the intricacies and essential knowledge involved in the research and development of the Coronil Kit - a combination of 3 ayurvedic medications for the common cold. It informs the reader about the huge potential of herbal drugs in fighting against any type of disease through evidence-based data of clinical trials and experiments. The book demonstrates how current scientific techniques can be applied to understand healing capacities of plants at their molecular level and thus utilizing their different natural product combinations to treat diseases by targeting harmful micro-organisms and simultaneously boosting the immune system. It covers methods of virtual screening and computational validation of identified phytochemicals as potential antiviral agents against the SARS-CoV-2 virus. Key features: 1. Covers the molecular etiology of COVID-19 virus, 2. Covers guidance on drug formulation, hazard assessment and clinical trials based on approved methods by regulatory organizations 3. Covers pharmacological, toxicological and technically verified chemical composition of medicinal plants 4. Includes information about in vivo experiments and analysis of Humanoid Zebrafish trials 5. Includes methods of identifying antiviral agents against SARS-CoV-2 virus 6. Includes chemical, analytical and technical studies of Coronil 7. Includes 70 informative colored figures over 7 chapters 8. Includes a bibliography and appendix The book is primarily intended as a primary resource for medical research scholars and researchers in pharmaceutical companies and as a secondary resource for B.A.M.S. students, medical postgraduate students and ayurveda enthusiasts.

The management of COVID-19 is challenging due to the lack of clear information about the Sars-Cov2 and recommendations for specific treatment regimens. The scale of the pandemic has also exacerbated the situation, with health care systems under stress from the high volume of COVID-19 patients.In Demystifying COVID-19: Understanding the Disease, Its Diagnosis, and Treatment, medical experts explain many aspects about the COVID-19 pandemic, including guidelines to minimize risk of infection, diagnostic methods, treatment, real scenarios in the course of the disease and issues that need attention in specific patient groups. The book equips both general readers and healthcare professionals with key information required to understand COVID-19 and navigate a situation typical to a pandemic. Public health officials who wish to mobilize awareness campaigns for the benefit of the general public can also find value in the comprehensive information presented in this reference. Key Features: - 16 chapters covering several aspects of COVID-19 including risk management, clinical diagnosis and treatment, public health issues and vaccines- Unique Q&A format which presents easy-to-understand information for all types of readers- Presents basic clinical information- Provides information for the management of COVID-19 in special patients (patients with comorbidities, the elderly, newborns, children, and pregnant women)- Bibliographic References for further reading

A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.

The etiologic agent of an outbreak of pneumonia in Wuhan, China, was identified as severe acute respiratory syndrome coronavirus 2 in January 2020. A patient in the United States was given a diagnosis of infection with this virus by the state of Washington and the US Centers for Disease Control and Prevention on January 20, 2020. We isolated virus from nasopharyngeal and oropharyngeal specimens from this patient and characterized the viral sequence, replication properties, and cell culture tropism. We found that the virus replicates to high titer in Vero-CCL81 cells and Vero E6 cells in the absence of trypsin. We also deposited the virus into 2 virus repositories, making it broadly available to the public health and research communities. We hope that open access to this reagent will expedite development of medical countermeasures.

Children with exposure to coronavirus disease 2019 in recent times (asymptomatic or symptomatic infection) approaching congenital heart surgery programme are in increasing numbers. Understanding outcomes of such children will help risk-stratify and guide optimisation prior to congenital heart surgery. The objective of the present study was to determine whether convalescent coronavirus disease 2019 children undergoing congenital heart surgery have any worse mortality or post-operative outcomes. Consecutive children undergoing congenital heart surgery from Oct 2020 to May 2021 were enrolled after testing for reverse transcription-polymerase chain reaction or rapid antigen test and immunoglobulin G antibody prior to surgery. Convalescent coronavirus disease 2019 was defined in any asymptomatic patient positive for immunoglobulin G antibodies and negative for reverse transcription-polymerase chain reaction or rapid antigen test anytime 6 weeks prior to surgery. Control patients were negative for any of the three tests. Mortality and post-operative outcomes were compared among the groups. One thousand one hundred and twenty-nine consecutive congenital heart surgeries were stratified as convalescence and control. Coronavirus disease 2019 Convalescent (n = 349) and coronavirus disease 2019 control (n = 780) groups were comparable for all demographic and clinical factors except younger and smaller kids in control. Convalescent children had no higher mortality, ventilation duration, ICU and hospital stay, no higher support with extracorporeal membrane oxygenation, high flow nasal cannula, no higher need for re-intubations, re-admissions, and no higher infections as central line-associated bloodstream infection, sternal site infection, and ventilator-associated pneumonia on comparison with coronavirus disease 2019 control children. Convalescent coronavirus disease 2019 does not have any unfavourable outcomes as compared to coronavirus disease 2019 control children. Positive immunoglobulin G antibody screening prior to surgery is suggestive of convalescence and supports comparable outcomes on par with control peers.